Proton therapy and cyclotrons market seen reaching $1.65 billion by 2030

The global market for proton therapy centers and high-capacity cyclotrons is projected to grow from $1.1 billion in 2026 to $1.65 billion by 2030, driven by rising cancer cases, precision oncology demand and new investment in radiation therapy infrastructure. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through the forecast period.

Why it matters: - Proton therapy centers and high-capacity cyclotrons are central to precision radiation therapy, which can target tumors while limiting damage to healthy tissue. - The market’s growth reflects rising cancer incidence, expanding oncology spending and broader adoption of advanced radiation treatment. - The category also signals where healthcare systems are directing capital for next-generation cancer care.

What happened: - The Business Research Company projected the global proton therapy centers and high-capacity cyclotrons market will rise from $1.1 billion in 2026 to $1.65 billion by 2030. - The forecast implies a 10.6% compound annual growth rate during the forecast period. - The report said the market stood at $1 billion in 2025. - North America held the largest market share in 2025. - Asia-Pacific is expected to post the fastest growth over the forecast period.

The details: - The report links historical growth to the rising global cancer burden, wider use of advanced radiation therapies, stronger demand for precision oncology, higher investment in cancer care infrastructure and greater awareness of fewer side effects tied to proton therapy. - The forecast period is expected to benefit from more proton therapy facilities worldwide, higher healthcare spending on oncology, improved reimbursement policies and growing demand for complex tumor treatment. - Public and private investment in particle therapy centers is also expected to support expansion. - Key trends cited in the report include pencil beam scanning, compact single-room proton therapy systems, more pediatric cancer use, expansion of multi-room proton therapy centers and greater use of organ-sparing radiation techniques. - Proton therapy systems use cyclotrons and synchrotrons to accelerate protons to near light speed. - The technology uses the Bragg Peak effect to deliver the highest dose to tumors while reducing exposure to surrounding tissue. - The report says the approach is especially suited to deep-seated, pediatric and anatomically challenging cancers. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report also includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspot infographics, and updated graphics and tables.

Between the lines: - The market’s growth path suggests proton therapy is moving from a niche treatment into a more established part of oncology infrastructure. - Faster growth in Asia-Pacific points to a buildout phase in regions expanding cancer treatment capacity. - Interest in compact systems and single-room setups suggests providers are seeking lower-footprint ways to add advanced therapy. - The December 2024 ScienceDirect projection cited in the report said global radiotherapy demand could reach about 21.2 million patients by 2050 at a 64% utilization rate, underscoring broader demand for radiation oncology capacity.

What's next: - More proton therapy centers are expected to come online as hospitals and treatment networks expand oncology services. - Reimbursement policy and capital investment will likely remain key drivers of adoption. - Product development appears headed toward smaller, more efficient systems and techniques that improve targeting and reduce side effects. - The report’s growth outlook indicates continued competition for share in both mature and emerging markets.

The bottom line: - Proton therapy and high-capacity cyclotrons are on track for steady double-digit growth as cancer care shifts toward more precise, tissue-sparing radiation treatment.